News and Trends 14 Jul 2022Beyond Biotech podcast 5: ANeuroTech, ISA Pharmaceuticals, Life Length This week’s guests are Erik Buntinx, CEO and founder of ANeuroTech; Stephen J. Matlin, CEO of Life Length; and Kees Melief, chief scientific officer at ISA Pharmaceuticals. ISA Pharmaceuticals’ clinical trial using AMPLIVANT technology A clinical trial using ISA Pharmaceuticals’ AMPLIVANT adjuvant technology started in April. The trial, run by partner Scancell Holdings plc is […] July 14, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jul 2022 Boston startup bags $40M Series A to smash preclinical bottlenecks The U.S. company Manifold Bio has raised $40 million in a Series A round to bankroll protein barcoding technology that could speed up the preclinical development of targeted cancer drugs. Two years after bagging a $5.4 million seed investment, the Boston-based protein drug developer Manifold Bio has hit the headlines with a $40 million round […] July 14, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jul 2022 GenScript ProBio enters strategic partnerships with two South Korean biotechs GenScript ProBio, the CDMO segment of the leading biotech GenScript, has entered into a strategic partnership memorandum of understanding (MOU) with DAAN Bio Therapeutics for the discovery and development of novel drugs and with ACT Therapeutics to develop new CAR-T cell therapies. With offices located in the U.S., the Netherlands, China, Singapore and Japan, GenScript […] July 14, 2022 - 3 minutesmins - By Omnia Ibrahim Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jul 2022 Agomab bags $114 million in thriving regenerative medicine sector The Belgian company Agomab Therapeutics has topped up its Series B round by $40.5 million to hit $114 million. This Pfizer-led financing round extension is just the latest sign that the emerging field of regenerative medicine is coming to the fore. Agomab has embarked on an ambitious path to redefine how we understand regenerative medicine […] July 14, 2022 - 3 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jul 2022 FDA authorizes the first protein-based COVID-19 vaccine in the US Novavax, Inc. has been given emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA) for its adjuvanted, protein-based COVID-19 shot. Branded Nuvaxovid and Covovax outside the U.S., Novavax’s vaccine is already approved for use in several countries worldwide, including the EU, U.K., Canada, Australia, South Korea and India. During public health emergencies, […] July 14, 2022 - 2 minutesmins - By Omnia Ibrahim Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jul 2022 Telo Genomics launches clinical study of drug resistance test for multiple myeloma Canadian biotech company Telo Genomics Corp. has started the processing of clinical samples to evaluate its TeloView platform to identify multiple myeloma (MM) patients at high-risk of developing treatment resistance. The study is the second being carried out in collaboration with the Mayo Clinic to evaluate the company’s prognostic technology to address multiple unmet clinical […] July 14, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 14 Jul 2022 Radiopharmaceuticals gain traction for cancer theranostics potential After decades of neglect from big pharma, radiopharmaceuticals are generating major oncology deals globally. This could lead to a boom in cancer drugs that can serve as both treatments and diagnostics, or “theranostics.” Over the last few years, there has been big activity from companies developing drugs that use radioactivity to destroy tumors. Just this […] July 14, 2022 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 13 Jul 2022 Paradigm of treatment of mental health to be transformed by gut-brain development program Building on a decade of research, a development program for next-generation probiotics and therapeutics to modulate gut microbiota and mental health has been launched. Seed Health, a microbiome science company along with Axial Therapeutics, a clinical stage biopharmaceutical company announced the joint program in the US today (July 13). It will build on the work […] July 13, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jul 2022 First aseptic filling line and facilities completed in Taiwan The construction of a fully-automated aseptic filling line and facilities has been finished in Taiwan. Amaran Biotechnology Inc., a subsidiary of Taiwan’s OBI Pharma Inc., made the announcement that the new facility, a first for the country, minimizes the risks of human factors affecting the quality of pharmaceutical products, and enhances their safety. The project […] July 13, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jul 2022 Orthox green light for knee cartilage repair clinical trial Orthox Limited, a clinical stage company developing medical implants to repair damaged knee articular cartilage and other orthopaedic injuries, can start its FFLEX (FibroFix cartilage repair experience) study. The company has received a Letter of No Objection from the UK’s MHRA, enabling the start of the study. The study, which is also supported by funding […] July 13, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jul 2022 Development of cancer therapeutics accelerated by end-to-end single-cell multi-omics services Solid tumor assays have been launched by Mission Bio Inc., through its Pharma Assay Development (PAD) services. The availability of this new service offering from Mission Bio, a high-throughput single-cell DNA and multi-omics analysis company, will help accelerate the development of cancer therapeutics. It will do so by reducing the time and cost associated with […] July 13, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jul 2022 Sanofi sells two portfolios of established products to Neuraxpharma Two drugs portfolios with products to treat the central nervous system, pain and vascular disease have been bought by pharmaceutical company, Neuraxpharm Group. The company bought the portfolios from French healthcare company, Sanofi. Jörg-Thomas Dierks, CEO of Neuraxpharm, said: “There is significant growth potential in the pharmaceutical sector, especially in the CNS market driven […] July 13, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email